Refractory Diffuse Large B-cell Lymphoma After First-line Immuno-CT: Treatment Options and Outcomes
概览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 104
- 试验地点
- 1
- 主要终点
- Outcome according to pattern of refractoriness
概览
简要总结
In the rituximab era, one-third of diffuse large B-cell lymphoma (DLBCL) patients experience relapse/refractory disease after first-line anthracycline-based immunochemotherapy (IChemo). Optimal management remains an unmet medical need. The aim of this study was to report the outcomes of a cohort of refractory patients according to their patterns of refractoriness and the type of salvage option. The investigators performed a retrospective analysis, which included 104 DLBCL patients treated at Lyon Sud University Hospital (2002-2017) who presented with refractory disease. The investigators retrospectively evaluated the outcomes of a cohort of 104 refractory patients according to their patterns of refractoriness and the type of salvage option.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years of age
- •diagnosed with DLBCL at Lyon Sud University Hospital (LSUH) from January 2002 to January 2017
- •presented with refractory disease in response to front-line therapies
- •including anthracycline-based chemo and a monoclonal anti-CD20 antibody
排除标准
- •Patients with a history of indolent lymphoma,
- •Patients with a primary central nervous system (CNS) lymphoma or immunosuppression-related lymphoma
结局指标
主要结局
Outcome according to pattern of refractoriness
时间窗: Up to 4 years
OS was defined as the time from first relapse, or progression, to death from any cause.
次要结局
- Outcome according to pattern of refractoriness(Up tp 24 months)